MacroGenics (MGNX) Q3 Earnings and Revenues Surpass Estimates

Core Insights - MacroGenics reported quarterly earnings of $0.27 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.48 per share, representing an earnings surprise of +156.25% [1] - The company posted revenues of $72.84 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 157.20%, although this is a decline from year-ago revenues of $110.71 million [2] - MacroGenics shares have underperformed, losing about 53.2% since the beginning of the year compared to the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $33.13 million, and for the current fiscal year, it is -$2.24 on revenues of $100.36 million [7] - The estimate revisions trend for MacroGenics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which MacroGenics belongs, is currently in the bottom 33% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]